A message from the EPAD Coordinators to all involved in the EPAD Longitudinal Cohort Study By now you will all be aware of the unexpected closure of the EPAD Longitudinal Cohort Study. We are writing to you to explain the background to this and also to thank you for your commitment to this research and the…
The EPAD team published a new paper entitled “Cognitive Functions as Predictors of Alzheimer’s Disease Biomarker Status in the European Prevention of Alzheimer’s Dementia Cohort” in the journal of Alzheimer’s disease. Abstract: Alterations in Alzheimer’s disease (AD) biomarkers have been observed decades before the onset of dementia. Cognitive dysfunction, while central to the clinical diagnosis…
What is your current role in EPAD? I co-lead WP2 (Statistical/Methodology Engine Room) and I am also a member of the Balancing Committee that has important input in the selection of individuals into the EPAD Longitudinal Cohort Study. I have been involved in different roles in various publications using the EPAD data. Tell us a…
What is your current role in EPAD? I work as a clinical lead at IQVIA where I manage the clinical research associates (CRAs) across all the countries that contribute to EPAD. I provide clinical trial expertise in accordance with protocols and with ICH GCP (International Conference on Harmonisation Good Clinical Practice). As clinical lead, I…
With the beginning of this new year, the EPAD project is celebrating its fifth birthday.
We are proud to look back at a lot of successful deliveries. We list herein some of our key highlights of the past 12 months.
Wishing you all an exciting and happy New Year,
The EPADistas.
The members of the EPAD initiative are glad to announce that its Longitudinal Cohort Study has recruited its 2,000th research participant in Sheffield (UK) this 15th January. Congratulations to the EPAD team in Sheffield (pictured). “Since we joined the project last year, patients in our area have been enthusiastic about the opportunities offered to them…
Abstract: Background: Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD). Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD pathology in individuals without dementia, especially among cognitively unimpaired. Prescreening on AD risk factors may facilitate recruitment, but the efficiency will depend on how…
Another EPAD year has passed and we are proud to look back at a lot of successful deliveries and established relationships. We are pleased to present some of our key achievements of the past 12 months. February On 4 February, over 90 representatives of the EPAD project met in Berlin for an investigator meeting. The…
This month, we get to know the Aeginition Hospital (Athens, Greece) centre behind EPAD. The team of Nikolaos Scarmeas (principal investigator of the EPAD project in Aeginition Hospital) began recruiting in September 2019 and has currently recruited 14 participants in the EPAD Longitudinal Cohort Study (LCS). We caught up with his team and asked them…
We would like to share the internal release of the baseline data from the first 1500 research participants (V1500.0) for the EPAD Longitudinal Cohort Study. The data set is now available and accessible to all EPAD partners and Trial Delivery Centres for an embargoed period of 6 months. Following which access will be opened to…
